IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 5, Issue 1, September 2025
Impact Factor: 7.67

Nanotech Science for Drug Delivery Platforms

Ankita Ashok Galande, Akshay Nana Budhe, Ganesh Ananda Gurav, Snehal Sanjay Didwagh
Mandesh Institute Pharmaceutical Science and Reserch Center, Mhaswad .

Abstract: *Nanotech science refers to a new approach in therapeutic delivery that uses very tiny particles, known as nanoparticles (1–100 nm), to deliver medicines directly to the affected region. The process enables one to minimize harmful side effects and increases the efficacy of treatments. It also makes disease diagnosis possible and makes it easier the crossing of barriers such as the blood-brain barrier. Different platforms including liposomes, polymeric nanoparticles, dendrimers, and gold nanoparticles have been designed for this reason. These nano platforms find applications in the treatment of cancer, gene therapy, vaccine delivery, and management of brain diseases. Preclinical trials on nano-based drugs such as Doxil®, Abraxane®, and Onivyde® have indicated promising outcomes. This technology has vast potential to revolutionize future medical therapies.*

Keywords: Nanotechnology, Drug Delivery Systems, Nanoparticles, Targeted Therapy, Controlled Release, Cancer Therapy, Liposomes, Dendrimers, Polymeric Nanoparticles, Inorganic Nanoparticles

I. INTRODUCTION

Nanotechnology creates materials at the nanometer scale (1–100 nm) that greatly influence medicine. Nanoparticles optimize drug delivery, lessen toxicity, and boost bioavailability, enhancing therapeutic efficiency and reducing side effects in biomedicine research.[1] Nanoparticle systems enhance medical and biological applications and enable photocatalysis, magnetic energy storage, sensing, and solar-energy conversion. [2]. Nanoparticles are essential for enhancing our understanding of material behavior at the nanoscale and the influence of quantum effects.
[3].

II. OVERVIEW OF DRUG DELIVERY PLATFORMS

Therapeutic delivery enhances treatments using safe approach's. Nanoscale advancements enhance pharmaceuticals, tackling challenges in food and cosmetics. Current platforms offer precise delivery and sustained release.[4] DDS enhances drug efficacy and safety with fewer molecules, improving stability, solubility, and patient compliance. A therapeutic delivery platform optimally transports therapeutic substances. Controlled delivery enhances safety, reduces dosing frequency, and enhances efficacy while minimizing side effects. [1] Controlled release dosage forms have evolved with new polymers and techniques to meet the demands of extended drug therapies.. [5].

III. MECHANISMS OF NANOPARTICLE DRUG DELIVERY

Nanotech science involves the manipulation and control of matter on a nanometer scale, typically from 1 to 100 nm [2]At this size, materials like particles, tubes, wires, films, and rods demonstrate unique properties, enabling diverse uses in medicine, biology, chemistry, IT, energy, environment, avionics, and food tech.
Nanotech is vital for drugs due to the nanoscale of many therapeutic molecules. Tailoring particle size optimizes circulation, improving targeted therapeutic delivery and therapeutic effects. [1]Nanoparticles offer benefits like customizable targeting, efficient delivery to disease sites, and controlled drug release, blending diagnostic and therapeutic functions into 'theranostic' agents. Their therapeutic delivery relies on passive and active targeting. Passive targeting utilizes the EPR effect for Nanoparticle accumulation in tumors, while active targeting modifies surfaces with Specific molecules to enhance localization and uptake by target cells.[6]

DOI: 10.48175/IJARSCT-28961

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 5, Issue 1, September 2025
Impact Factor: 7.67

3.1. Passive Targeting

The passive targeting mechanism employs Nano carriers to deliver drugs to tumor cells diffusing through capillary pores. Particles under 150 nm are common in oncotherapy due To tumor capillary permeability, allowing 250 nm nanoparticles to accumulate at tumor sites. [7]

3.2. Active Targeting

Active targeting relates to engineering drug-delivery vehicles to selectively target cancer cells and other disease targets and bind to them to release the load, effectively enhancing the therapeutic efficacy and reducing plat formic side effects [7]. This approach uses ligands on Nano carriers to enhance tumor targeting. Drug-loaded carriers enhance efficacy and reduce side effects. Covalent binding increases tumor accumulation while minimizing toxicity. Delivery to organelles inducing cell death depends on the Nano carrier's size, shape, and surface properties[8]

IV. TYPES OF NANOPARTICLES IN DRUG DELIVERY

Nanoparticles like liposomes and dendrimers are applied in medicine. Liposomes, made of phospholipid vesicles, encapsulate drugs. Their drug distribution and release depend on size, membrane composition, and preparation approach, enhancing delivery and reducing toxicity.[9] [6]. Dendrimers enhance therapeutic delivery, affecting therapy and toxicity. Biodegradable polymeric nanoparticles' delivery and toxicity depend on size, charge, and coatings. Inorganic nanoparticles, such as gold, offer controlled shape and size but may have heavy-metal toxicity risks.[10]

4.1. Liposomes

Liposomes are preferred for therapeutic delivery because of their targeting, solubility, and stability, enhancing therapeutic effects with nanoscale design and phospholipid bilayer modifications.[11] Drug- loaded vesicles typically comprise a hydrophilic interior and one or more concentric phospholipid bilayers or lipid monolayers .[12] Therapeutic agents target specific cells to reduce side effects. Nano liposomes serve as smart carriers for anticancer and anti-inflammatory drugs. Iontophoresis enhances delivery, demonstrating good biomedical compatibility. Cholesterol-stabilized phospholipids enable controlled therapeutic release. [13]

4.2. Dendrimers

Dendrimers are tiny, highly branched macromolecules with a core, uniformity, specific shape, and narrow weight distribution. [14]. Dendrimers are ideal for therapeutic delivery due to endocytosis uptake, biocompatibility, solubility, and specific weight, enabling multi-drug transport. Dendrimers can be easily internalized by cells through endocytosis to transport drugs, making them effective therapeutic delivery devices. Dendritic structures encapsulate drugs for targeted delivery, enhancing solubility and reducing side effects. [15]

4.3. Polymeric Nanoparticles

Nano medicine has enabled therapeutic delivery platforms that enhance bioavailability, efficacy, and reduce toxicity. [16]. Nanoparticles, ranging from 10 to 1000 nm, are vital for overcoming biological barriers and enhancing therapeutic delivery, signaling future medical advances.

4.4. Inorganic Nanoparticles

Inorganic nanoparticles possess highly-tailored magnetic, optical and electronic properties that can be tuned by size and shape [9]. The stability of inorganic nanoparticles is their main advantage, along with superior mechanical and thermal properties.[5]. The surface and porosity of particles are crucial for delivering functional molecules. Key factors include size, shape, surface chemistry, flexibility, and biodegradability, so controlling nanocarrier dimensions is essential for effective delivery. Inorganic nanoparticles play a vital role in therapeutic delivery and imaging, enhancing controlled release and reducing toxicity

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 5, Issue 1, September 2025
Impact Factor: 7.67

V. SYNTHESIS OF NANOPARTICLES

Nanoparticle synthesis employs top-down and bottom-up approach's, emphasizing biological processes for safety and simplicity. Factors such as phase, size, shape, and composition impact performance. Size affects shape and catalytic efficacy, necessitating characterization through dynamic light scattering, UV-vis spectrometry, and electron microscopy.

5.1. Top-Down Approaches

Top-down processing reduces size with high shear energy but risks degradation, while bottom-up synthesis shapes from a solution.[18] Standard nanoparticle synthesis uses bead milling and high-pressure homogenization. Low-energy approach's don't form a Nano matrix, while optimized homogenizers achieve effective size reduction.5.2. Bottom-Up Approaches Bottom-up approach's involve the self-assembly of molecular components through intermolecular forces to construct nanostructured particles [18]. Controlling particle size and shape enhances milling for nano and micro-sized particles, boosting drug bioavailability.

Nanotech science advancements enhance drug transport, highlighting multifunctional particles and scalable production.

5.2. Bottom-Up Approaches

Bottom-up approach involve the self-assembly of molecular components through intermolecular forces to construct nanostructured particles [18]. Controlling particle size and shape enhances milling for nano and micro-sized particles, boosting drug bioavailability. Nanotech science advancements enhance drug transport, highlighting multifunctional particles and scalable production

VI. CHARACTERIZATION TECHNIQUES FOR NANOPARTICLES

Characterizing nanoparticles is vital for targeted therapeutic delivery since size, shape, and mechanisms affect function and penetration. Many approach are limited or destructive, restricting bulk solution use.

Techniques like dynamic light scattering (DLS) and nano tracking analysis (NTA) offer rapid, non- destructive measurements addressing key issues. While size distribution approach can distort aspect ratios, average sphere size is crucial for particles in narrow biomass pores. DLS evaluates nanoparticles (NPs), focusing on strong scattering from aggregation, which is vital for modeling iron oxide NPs in therapeutic delivery, as size, shape, and agglomeration affect therapeutic release.[19]

6.1. Dynamic Light Scattering

Dynamic light scattering (DLS), or photon correlation spectroscopy, analyzes Brownian motion to measure scattered light and correlate it to particle size. [19] The technique analyzes scattering fluctuations from Brownian motion in suspended particles, crucial for size analysis. DLS employs a laser to gather scattered light at 90°, with intensity fluctuations reflecting the particle size distribution in the sample. DLS assumes smaller particles move faster and fluctuate more in scattered light than larger ones. The measured size is the hydrodynamic radius, similar to a hard sphere diffusing like the particle.

6.2. Transmission Electron Microscopy

Transmission electron microscopy (TEM) is vital for nanoparticle research. In vitro tests enhance conditions, reduce costs, and minimize animal testing. Safety assessments should focus on cell death signals, as necrosis or apoptosis can provoke inflammation. TEM on ultrathin sections is key for identifying cellular damage. TEM demonstrates nanoparticle shape and size, indicating aggregation, while Cryo-EM preserves structures for therapeutic delivery. Cryo-TEM highlights lipid or polymer-stabilized Nano bubbles. Extracellular vesicles (EVs) are crucial in biology, diseases, and therapeutic delivery. Cryo-EM visualizes EV populations and subclasses essential for signaling. Stem-cell vesicles transport drugs, while Cryo-TEM differentiates debris from empty vesicles. It also facilitates single-particle protein analysis in structural biology.[21][22]

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 5, Issue 1, September 2025
Impact Factor: 7.67

6.3. Electron Microscopy

The electron microscope, developed in the 1930s, is crucial for studying nanostructures, offering atomic-level details on size and shape. Recent advancements enable it to operate at 20 nm, distinguishing forms from compositions. Common SEM variants include ESEM, Cryo-SEM, LP-SEM, and VP-SEM. ESEM captures hydrated samples in gas, Cryo-SEM uses cryogenic preservation, and LP-SEM enhances resolution for wet specimens. [20}

VII. DRUG LOADING MECHANISMS

Some drugs are incorporated into nanoparticles for delivery platforms through physical adsorption or chemical conjugation [4]

7.1. Physical Adsorption

Physical adsorption is essential for loading therapeutic agents onto nanoparticles in therapeutic delivery. Research focuses on improving lipid nanoparticles for targeted drug and gene delivery.[23] Molecular dynamics simulations demonstrate that functionalized carbon nanotubes enhance therapeutic delivery and release of doxorubicin and paclitaxel, improving pharmacotherapy. [24]

7.2. Chemical Conjugation

In general, drugs are loaded into nanoparticles either via physical adsorption or through chemical conjugation to the nanoparticle surface [25]. Drug conjugates are pharmacologically inactive or less active derivatives of drug molecules, often utilized to augment solubility or optimize pharmacokinetic profiles [26]. Nanoparticle drug conjugates link therapeutic agents to nanoparticles for metabolism studies. Amphiphilic prodrugs combine hydrophobic and hydrophilic elements, while peptide-drug conjugates enhance transport with stable linkers.

VIII. RELEASE MECHANISMS OF DRUGS FROM NANOPARTICLES

Drug release from nanoparticles can be diffusion-controlled or chemically controlled. In diffusion-controlled release, drugs diffuse into the medium, with the release rate affected by drug and fluid properties.

Chemically controlled release involves breaking bonds between drug and polymer chains through enzymatic or hydrolytic processes. Selective release can happen due to physiological pH and enzyme activity at the target site, as demonstrate by a pH-responsive nanocarrier. [1]

8.1. Diffusion-Controlled Release

Many therapeutic delivery platforms utilize nanoparticles for enhanced drug penetration via diffusion - controlled release, resulting in a rapid initial burst effect. Polymeric drug-delivery platforms commonly release drugs by diffusion, characterized by an initial burst followed by slower release [27]. Platforms like multiporous aerogel microspheres present controlled release of acetylsalicylic acid with sustained and prolonged therapeutic delivery [28].

8.2. pH-Responsive Release

Chemotherapeutic agents struggle with low drug release in tumors, and pH-sensitive delivery platforms can enhance this by activating drugs in acidic environments (pH 6.5–7.2). These platforms also utilize pH- sensitive nanoparticles (100 to 20 nm) to enhance transport and accumulation through the EPR effect and endocytosis. [29] Various nanoparticle platforms, including magnetic nanoparticles, gold nanoparticles, mesoporous silica nanoparticles, and micelles, have been exploited for cancer therapy, many exhibiting pH- triggered drug-release behavior [30]. Materials that swell or dissolve at pH 5.0–7.0 enable targeted drug release in acidic tumor regions.

IX. THERAPEUTIC APPLICATIONS OF NANOTECH SCIENCE

Nanotech science supports over 20 anticancer therapies, including antibody-based treatments. Antibody- drug conjugates aid in overcoming tumor resistance, and nano medicines under 300 nm boost drug concentrations in tumors.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 5, Issue 1, September 2025
Impact Factor: 7.67

Liposomal formulations enhance poorly soluble antibiotics, while vaccine nanoparticles enhance antigen presentation, leading to stronger antibody responses with lower doses than standard vaccines. [1]

9.1. Cancer Treatment

Cancer poses a significant global health challenge, with treatments such as chemotherapy and radiotherapy damaging healthy cells as well as tumor cells. The aim is to minimize this harm while targeting tumors effectively. Traditional approach employ non-selective chemotherapeutics that accumulate in tumors due to enhanced permeability retention. [31]Agents are spread throughout the body and typically excreted by the kidneys, limiting their effectiveness. Low molecular mass chemotherapeutics struggle with low response rates, resistance, and poor tumor selectivity. [32]Nanotech science is crucial for creating selective, efficient, and safer medicines. Nano medicine uses unique properties of structures in the 8–100 nm range to develop advanced therapeutics. Nanoparticle-based therapeutic delivery platforms (DDS) enable targeted therapeutic delivery, enhancing efficacy and reducing plat formic toxicity, while addressing resistance and preventing aggressive disease recurrence. Nanocarriers that selectively accumulate in tumors significantly enhance cancer treatment by delivering highly toxic agents with minimal effects on healthy cells. This field is emerging as a critical tool for effective tumor theranostics, with increasing studies and development of nano medicines in clinical use or trials. The development of these nanocarriers marks a major breakthrough in cancer treatment, allowing for the delivery of cytotoxic agents effectively while minimizing side effects on healthy tissues. Thus, nanotech science is becoming an essential tool in seeking new, effective tumor theranostics, as evidenced by the growing body of scientific research and the approval of several nanomedicines for clinical use. [33]

9.2. Antibiotic Delivery

Conventional antibiotics face challenges like low therapeutic index, resistance, and toxicity. Nanocarriers enhance targeted delivery and reduce side effects. Active nanovectors offer dual therapy, while viral vectors target bacteria but may have safety risks. Research aims to develop safer carriers to boost antibiotic levels at infection sites and fight resistance.

9.3. Vaccination

Vaccine development with nanotech science is crucial for combating pathogens, especially in biomedicine, due to rising global demand for effective solutions against infectious diseases and cancer. [33] The development of mRNA lipid nanoparticle vaccines for COVID-19 highlights the potential of nanovaccines for infectious diseases. Nanoparticles serve as nanovaccines or adjuvants with varied structures. Vaccine safety and efficacy are crucial. Liposomes and lipid nanoparticles receive regulatory backing, improving vaccines and advancing global health.

X. CHALLENGES IN NANOPARTICLE DRUG DELIVERY

The rapid development of nanotech science enhances therapeutic delivery using nano-sized constructs that enhance stability and circulation time. Challenges remain before clinical studies advance. [5] A nanodrug platform uses nano-scale particles to enhance therapeutic delivery, with geometry impacting loading efficiency, making efficient fabrication vital for production Administering nanodrugs in clinical research raises costs due to complex designs, safety, regulatory issues, and IP concerns. Additionally, creating metallic nanoparticles incurs expenses and risks, such as immune reactions and ingredient loss from filtering 220 nm particles.

10.1. Toxicity Concerns

Current evidence for the aggregate toxicity of nanoparticles remains ambiguous [35]In vivo toxicity concerns focus on pulmonary, oral, dermal exposure to ultrafine particles, and parenteral administration. [36]

10.2. Regulatory Issues

Nanotech science enables engineers and scientists to control particles at a dimension less than 100 nm according to their size, surface, shape, and distribution [37]

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 5, Issue 1, September 2025
Impact Factor: 7.67

XI. FUTURE PERSPECTIVES IN NANOTECH SCIENCE

Owing to nanotech science's ability to interface with the complex part of human physiology effectively, it is poised to advance medicine by underpinning personalized healthcare [18]Smart therapeutic delivery platforms using nanotech science personalize treatments, intervene early, and continuously monitor health. By targeting changes in cell-surface receptors, ligand-conjugated nanoparticles enable effective, tailored therapeutic delivery. [2] When combined with tools like blood-based metabolite profiling and advanced imaging, these receptor-targeted nanomedicines could make it possible to spot diseases earlier, monitor health in real time, intervene more effectively, and design treatments tailored to each individual.

11.1. Personalized Medicine

Since the early 2000s, nanotech science in medicine has focapplied on improving cellular functions. A key challenge is delivering non-toxic materials to minimize degradation. Nanoparticle carriers enhance personalized medicine by boosting efficacy and lowering side effects. [38]

11.2. Smart Drug Delivery

Targeting organs with therapeutic agents is tough. Smart nano-platforms employ polymers and hydrogels for controlled release, while 2D materials enhance transport. The two dimensional materials concept began with Wallace in 1947, centering on graphene. It emerged in 2004 through graphite exfoliation, allowing smart therapeutic delivery platforms to release therapeutic agents using stimuli.[39].

XII. ETHICAL CONSIDERATIONS IN NANOTECH SCIENCE

Nanotech science will revolutionize healthcare through nanomedicine, enabling early disease detection via tissue sample analysis. It offers targeted therapeutic delivery with minimal side effects. Tools like polymeric micelles and dendrimers efficiently transport drugs, solving water-insoluble medication problems and allowing customizable delivery based on pH or temperature.[40].Nanoparticle toxicity necessitates safer production approach's and solvents. A risk-benefit analysis of new nanomaterials is essential to minimize human hazards. In nanomedicine, self-assembly issues in dendrimers and carbon nanotubes affect genetic material, highlighting the need for biodegradable disposal materials to reduce growth risks.

XIII. CASE STUDIES ON NANOTECH SCIENCE IN DRUG DELIVERY

The beneficial effects of thermosensitive micelles and nanoparticles are demonstrate by Examples of nanotech science in recent trials or drug market entry. [3] . BIND-014, a Docetaxel nano formulation, offers reduced clearance and enhanced efficacy compared To free docetaxel. NC-6004, a cisplatin nanoparticle, demonstrates antitumor effects while Reducing nephrotoxicity. [4]. Clinical studies on NC-6004 with gemcitabine or Pembrolizumab target head and neck and lung cancers. [1]

13.1. Clinical Trials

Engineered inorganic nano-sized materials in drug formulations have crucial therapeutic Roles.[41]. Clinical trials face challenges with iron oxide nanoparticles as MRI contrast Agents, including safety and biological barriers. [42]. Extrapolating animal model data to Humans is challenging due to physiological differences. Effective assays need Randomization, blinding, and controls. Regulatory bodies enforce safety standards, and Trials in nanomedicine confront size and dosing issues. Innovations such as Patisiran/ONPATTRO and VYXEOS utilize nanoparticle platforms.[43]

13.2. Market Approvals

Agencies like FDA, EMA, and MHLW/PMDA offer guidelines for nanotech science medical Products, including Reflection Papers on liposomes and micelles. The FDA reviews Products individually and has approved Doxil®, DaunoXome®, and Marqibo®. Around 100Nanotech science therapeutics are in clinical trial

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 5, Issue 1, September 2025
Impact Factor: 7.67

XIV. CONCLUSION

Nanotech science is essential in medicine for therapeutic delivery and imaging, enhancing Permeability and surface area. [1]. Nanoscale technologies enhance therapeutic delivery through Enhanced solubility, targeting, and sustained release. [2]. Nanomaterials, potential drugs, And biomolecules enhance release, solubility, bioavailability, and Targeting.[5].Nanoparticles effectively carry therapeutic agents, improving combination Therapy and minimizing side effects, dose, and toxicity. Enhanced therapeutic delivery is essential Due to short lifespans and side effects of traditional approach's. Nanoparticles boost Targeting and bioavailability, emphasizing the importance of nanotech science[42]

REFERENCES

[1] S. Singh Suri, H. Fenniri, and B. Singh, "Nanotechnology-based drug delivery systems," 2007. Ncbi.nlm.nih.gov
[2] K. Sonamuthu, "Applications of Nanotechnology in Drug Delivery Systems," 2019. [PDF]
[3] S. Su and P. M. Kang, "Recent Advances in Nanocarrier-Assisted Therapeutics Delivery Systems," 2020. Ncbi.nlm.nih.gov
[4] S. Huang and X. Ding, "Precise Design Strategies of Nanotechnologies for Controlled Drug Delivery," 2022. Ncbi.nlm.nih.gov
[5] Y. Liu, Y. Liang, J. Yuhong, P. Xin et al., "Advances in Nanotechnology for Enhancing the Solubility and Bioavailability of Poorly Soluble Drugs," 2024. Ncbi.nlm.nih.gov
[6] 임은경 and 허용민 , "Delivery of Cancer Therapeutics Using Nanotechnology," 2013. [PDF]
[7] J. Li, Q. Wang, G. Xia, N. Adilijiang et al., "Recent Advances in Targeted Drug Delivery Strategy for Enhancing Oncotherapy," 2023. Ncbi.nlm.nih.gov
[8] S. M. Roy, V. Garg, S. Barman, and C. Ghosh, "Kinetics of Nanomedicine in Tumor Spheroid as an In Vitro Model System for Efficient Tumor-Targeted Drug Delivery With Insights From Mathematical Models," *Frontiers in Bioengineering and Biotechnology*, vol. 2021. Frontiersin.org
[9] D. Singh Khatra, S. L Harikumar, and N. Nirmala, "Nanoparticles: An Overview," 2013. [PDF]
[10] V. Rastogi, P. Yadav, M. Porwal, S. Sur, "Dendrimer as nanocarrier for drug delivery and Drug targeting therapeutics: a fundamental to advanced systematic review," International Journal of …, 2024. [HTML]
[11] M. P. Nikolova, E. Manoj Kumar, and M. S. Chavali, "Updates on Responsive Drug Delivery Based on Liposome Vehicles for Cancer Treatment," 2022. Ncbi.nlm.nih.gov
[12] K. M. Aguilar-Pérez, J. I. Avilés-Castrillo, D. I. Medina, R. Parra-Saldivar et al., "Insight Into Nanoliposomes as Smart Nanocarriers for Greening the Twenty-First Century Biomedical Settings," 2020. Ncbi.nlm.nih.gov
[13] S. Majumdar, B. Mahanti, A. K. Kar, H. Parya, A. Ghosh, "Nanoliposome: As a smart Nanocarrier in transdermal drug delivery system," Intelligent…, vol. 2024, Elsevier. Sciencedirect.com
[14] N. Thuy Trang Le, T. Nhu Quynh Nguyen, V. Du Cao, D. Thuan Hoang et al., "Recent Progress and Advances of Multi-Stimuli-Responsive Dendrimers in Drug Delivery for Cancer Treatment," 2019. Ncbi.nlm.nih.gov
[15] T. Haribabu and P. M. Manjunatha, "Development of Dendrimer-Flurouracil and Folic Acid Conjugation for the Treatment of Colon Cancer via Target Drug Delivery," RGUHS Journal of Pharmaceutical, 2023. Journalgrid.com
[16] G. Singh, A. Faruk, and P. Mohinder Singh Bedi, "Technology Overview and Current Biomedical Application of Polymeric Nanoparticles," 2018. [PDF]
[17] R. De, M. K. Mahata, and K. T. Kim, "Structure‐based varieties of polymeric Nanocarriers and influences of their physicochemical properties on drug delivery profiles," Advanced Science, 2022. Wiley.com
[18] T. Panagiotou and R. J. Fisher, "Enhanced Transport Capabilities via Nanotechnologies: Impacting Bioefficacy, Controlled Release Strategies, and Novel Chaperones," 2011. Ncbi.nlm.nih.gov
[19] O. George, "Synthesizing multifunctional iron oxide nanodrugs and developing a model For their size analysis using dynamic light scattering," 2019. [PDF]
[20] E. Di Cola, I. Grillo, and S. Ristori, "Small Angle X-ray and Neutron Scattering: Powerful Tools for Studying the Structure of Drug-Loaded Liposomes," 2016. Ncbi.nlm.nih.gov

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 5, Issue 1, September 2025
Impact Factor: 7.67

[21] N. Koifman and Y. Talmon, "Cryogenic Electron Microscopy Methodologies as Analytical Tools for the Study of Self-Assembled Pharmaceutics," 2021. Ncbi.nlm.nih.gov
[22] M. Malatesta, "Transmission Electron Microscopy for Nanomedicine: Novel Applications for Long-established Techniques," 2016. Ncbi.nlm.nih.gov
[23] Q. Shu, P. Huang, Z. Dong, and W. Wang, "Molecular dynamics investigation on Synthesis of a pH- and temperature-sensitive carbon nanotube loaded with doxorubicin," 2024.Ncbi.nlm.nih.gov
[24] M. Rezaian, R. Maleki, M. Dahri Dahroud, A. Alamdari et al., "pH-Sensitive CoAdsorption/Release of Doxorubicin and Paclitaxel by Carbon Nanotube, Fullerene, and Graphene Oxide in Combination with N-isopropylacrylamide: A Molecular Dynamics Study," 2018. Ncbi.nlm.nih.gov
[25] Q. Feng and R. Tong, "Anticancer nanoparticulate polymer‐drug conjugate," 2016. Ncbi.nlm.nih.gov
[26] W. Zhang, R. Taheri-Ledari, F. Ganjali, F. Hassanzadeh Afruzi et al., "Nanoscale Bioconjugates: A review of the structural attributes of drug-loaded nanocarrier conjugates For selective cancer therapy," 2022. Ncbi.nlm.nih.gov
[27] J. Jackson, A. Chen, H. Zhang, H. Burt et al., "Design and Near-Infrared Actuation of a Gold Nanorod–Polymer Microelectromechanical Device for On-Demand Drug Delivery," 2018. Ncbi.nlm.nih.gov
[28] S. Talasila, "Organically Functionalized Multiporous Alumino-Siloxane Aerogel Microspheres For Controlled Release Of Antiplatletic Drug Aspirin.," 2014. [PDF]
[29] W. Wu, L. Luo, Y. Wang, Q. Wu et al., "Endogenous pH-responsive nanoparticles with Programmable size changes for targeted tumor therapy and imaging applications," 2018. Ncbi.nlm.nih.gov
[30] 허용민 , 서진석 , 이훈재 , 임은경 et al., "Chitosan-based intelligent theragnosis Nanocomposites enable pH-sensitive drug release with MR-guided imaging for cancer Therapy," 2013. [PDF]
[31] F. Rodríguez, P. Caruana, N. De la Fuente, P. Español et al., "Nano-Based Approved Pharmaceuticals for Cancer Treatment: Present and Future Challenges," 2022. Ncbi.nlm.nih.gov
[32] C. Misra, M. Gaur, and L. Narayan Gupta, "Nanotechnology: Emerging Platform for Drug Based Delivery System in Cancer," 2019. [PDF]
[33] R. Pati, M. Shevtsov, M. Shevtsov, M. Shevtsov et al., "Nanoparticle Vaccines Against Infectious Diseases," 2018. [PDF]
[34] C. Feng, Y. Li, B. Emiliano Ferdows, D. Neal Patel et al., "Emerging vaccine Nanotechnology: From defense against infection to sniping cancer," 2022. Ncbi.nlm.nih.gov
[35] Z. Hursarsky, "Nanotechnology," 2015. [PDF]
[36] K. L. Aillon, Y. Xie, N. El-Gendy, C. J. Berkland et al., "Effects of nanomaterial Physicochemical properties on in vivo toxicity," 2017. [PDF]
[37] J. Sun, Z. Yang, and L. Teng, "Nanotechnology and Microtechnology in Drug Delivery Systems," 2020. Ncbi.nlm.nih.gov
[38] M. J. Mitchell, M. M. Billingsley, R. M. Haley, M. E. Wechsler et al., "Engineering Precision nanoparticles for drug delivery," 2020. Ncbi.nlm.nih.gov
[39] H. Zhang, T. Fan, W. Chen, Y. Li et al., "Recent advances of two-dimensional materials In smart drug delivery nano-systems," 2020. Ncbi.nlm.nih.gov
[40] M. Ebbesen and T. G. Jensen, "Nanomedicine: Techniques, Potentials, and Ethical Implications," 2006. Ncbi.nlm.nih.gov
[41] V. Weissig and D. Guzman-Villanueva, "Nanopharmaceuticals (part 2): products in the Pipeline," 2015. Ncbi.nlm.nih.gov
[42] T. I. Ramos, C. A. Villacis-Aguirre, K. V. López-Aguilar, L. Santiago Padilla et al., "The Hitchhiker's Guide to Human Therapeutic Nanoparticle Development," 2022. Ncbi.nlm.nih.gov
[43] A. C. Anselmo and S. Mitragotri, "Nanoparticles in the clinic: An update," 2019. Ncbi.nlm.nih.gov